Hanmi Pharmaceutical (128940) disposed of 11,180 common treasury shares to employees and officers on August 4 at KRW 345,500, the prior day's close, for a total of KRW 3.86 billion, the company said in a filing.
The filing's own reconciliation table flags the outcome as inconsistent with what Hanmi originally scheduled: 10,402 shares planned versus 11,180 actually distributed. The company attributes the gap to share-price movement and performance-evaluation results in the period between the board's disposal decision and the actual settlement date. Korean disclosure rules require this match-or-mismatch field on every treasury disposal result report.
Separately, the filing notes Hanmi holds another 110,700 treasury shares acquired for a specific statutory purpose that are excluded from this transaction entirely.
The KRW 3.86 billion distributed compares with Hanmi's KRW 6,072.4 billion market capitalization and FY2025 revenue of KRW 1,547.5 billion; at 0.25% of revenue, it is immaterial financially but notable for the disclosed shortfall between plan and outcome.
1,547.5 billion won FY2025 revenue.
kstock reads DART every morning and writes up what moved — the contract, the buyback, the number that does not add up. The daily post and a Saturday roundup, by email.
| Symbol | Last Price |
|---|---|
| 128940Hanmi Pharm. Co., Ltd. | ₩473,500 +2.8% |